What is Nasus Pharma Ltd. (NSRX)?

Nasus Pharma Ltd. (NSRX) is a stock in the Healthcare sector, Medical - Pharmaceuticals industry. View full analysis on Stocks360.

What is the current price of NSRX?

The current price of NSRX is $3.07. Prices are updated in real time on Stocks360.

What is NSRX's price-to-earnings (PE) ratio?

NSRX's trailing twelve-month PE ratio is -2.99, based on current price and earnings per share data available on Stocks360.

What is NSRX's market capitalization?

NSRX's market capitalization is $26,441,621.00, placing it in the small-cap tier.

Nasus Pharma Ltd. (NSRX)

Stock analysis · AMEX · Healthcare · Medical - Pharmaceuticals

$3.07

Market Cap

$26.44M

PE (TTM)

-2.99

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

4.20

Day Range

$3.07 – $3.27

52-wk Range

$1.98 – $9.50

Avg Volume

N/A

Volume

4.89K

Nasus Pharma Ltd. (NSRX) is a publicly traded company in the Healthcare sector. Latest price: $3.07. Market cap $26.44M. Trailing PE -2.99. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $7.78 2026-10-30 · $3.07 (-60.54%)

Earnings

Most Recent

Aug 17, 2026

EPS $-0.54 vs est. $-0.27

Missed by $0.27

Next Earnings

Mar 3, 2027

EPS estimate $-0.73

Proprietary Signals

Signal snapshot temporarily unavailable.

About Nasus Pharma Ltd.

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.99×
P/S (TTM)	0.00×
P/B	3.09×
PEG	0.03×
P/FCF (TTM)	-7.86×
EV / EBITDA	-2.61×
EV / Sales	0.00×
Earnings Yield	-32.16%
Free Cash Flow Yield	-12.72%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$18.73M
Net Income (TTM)	-$8.50M
Free Cash Flow (TTM)	-$3.36M
Net Debt	-$7.71M
Working Capital	$10.91M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-158.83%
Return on Invested Capital	-96.46%